| Paris | |
| 30 | |
| Hybrigenics is a bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Hybregenics services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells. | |
| Hybrigenics is committed to developing inecalcitol for the treatment of cancers, such as prostate cancer, chronic lymphocytic leukemia and chronic myeloid leukemia. Inecalcitol is a vitamin D receptor agonist which is significantly more potent and less toxic than its natural equivalents. Deubiquitinating enzymes (DUBs) are proteases involved in the recycling of cellular proteins. By blocking the degradation of these proteins, DUBs act on disease mechanisms during which deregulated proteins accumulate or act in an uncontrollable manner. Therefore, DUB inhibitors are emerging as promising pharmacological targets against diseases of a proliferative, cancerous, inflammatory or degenerative nature. Hybrigenics has gained unique insights and expertise in the field of DUBs which it applies to the discovery and development of new treatments under an exclusive partnership with Servier in six therapeutic areas. Phase IIa is completed for the oral inecalcitol in castrate-resistance prostate cancer, and phase II ongoing for the oral inecalcitol in chronic lymphocyitic leukemia. |
|
| DELANSORNE Remi | |
| www.hybrigenics.com | |
| ALHYG:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 25 fois.